<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00379600</url>
  </required_header>
  <id_info>
    <org_study_id>ARA102198</org_study_id>
    <nct_id>NCT00379600</nct_id>
  </id_info>
  <brief_title>The Anti-Inflammatory And Metabolic Effects Of Rosiglitazone In Subjects With Rheumatoid Arthritis</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Anti-inflammatory and Metabolic Effects of Rosiglitazone XR, 8mg Once Daily, in Subjects With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess whether the anti-inflammatory effects of rosiglitazone result in improvements in&#xD;
      Rheumatoid Arthritis symptoms in patients for whom their existing Disease Modifying&#xD;
      Anti-Rheumatic Drug (DMARD) treatment does not give adequate relief.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Activity Score (DAS) following 6 months of treatment</measure>
    <time_frame>6 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease activity at 3 months and 6 months, e.g., number of affected joints Patient Assessments of Improvements in Disease Activity, e.g., fatigue and pain assessment Assessment of safety, tolerability and biological activity</measure>
    <time_frame>Disease activity at 3 months and 6 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">96</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosiglitazone XR</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Rheumatoid Arthritis insufficiently controlled by existing disease-modifying&#xD;
             anti-rheumatic drugs&#xD;
&#xD;
          -  Subjects will have at least 6 swollen joints plus 2 of the following: 6 tender joints&#xD;
             (of 28 joints); early morning stiffness lasting more than 30 minutes; ESR greater or&#xD;
             equal to 28mm/h&#xD;
&#xD;
          -  must be receiving a stable dose of disease-modifying anti-rheumatic therapy for at&#xD;
             least 2 months prior to participating in the study.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Women who are lactating, pregnant, or planning to become pregnant during the course of&#xD;
             the study including 30 days following conclusion of study medication&#xD;
&#xD;
          -  Systolic blood pressure (SBP) &gt;165 mmHg or diastolic blood pressure (DBP) &gt;95 mmHg&#xD;
             while receiving optimal antihypertensive therapy&#xD;
&#xD;
          -  Any clinically significant abnormality identified on the screening physical exam,&#xD;
             laboratory tests, or ECG, which in the judgement of the Investigator makes the subject&#xD;
             unsuitable for inclusion in the study&#xD;
&#xD;
          -  a history of alcohol abuse within the past 3 years or consumes &gt;3 units per day for&#xD;
             males and &gt;2 units per day for females or has a history of cirrhosis or stigmata of&#xD;
             chronic liver disease&#xD;
&#xD;
          -  a history of liver disease or has alanine aminotransferase (ALT) or aspartate&#xD;
             aminotransferase (AST) levels &gt;2.5 times upper limit of normal and total bilirubin&#xD;
             levels greater than 1.5 times the upper limit of normal (unless associated with&#xD;
             predominantly indirect bilirubin or Gilbert's syndrome) at screening&#xD;
&#xD;
          -  using glucocorticoid at doses &gt;10 mg/day currently or within the last 3 months or may&#xD;
             be expected to do so during the course of the study&#xD;
&#xD;
          -  The subject's dose of NSAIDs, COX-2 inhibitors or glucocorticoids has changed at any&#xD;
             time during the past 2 weeks prior to screening or may be expected to change during&#xD;
             the course of the study&#xD;
&#xD;
          -  The subject's dose or treatment with a statin has changed at any time during the past&#xD;
             3 months prior to screening or may be expected to change during the course of the&#xD;
             study&#xD;
&#xD;
          -  a history of renal disease or has serum creatinine = 132mol/L for males and =130mol&#xD;
             for females&#xD;
&#xD;
          -  has diabetes mellitus that requires medication or hyperglycaemia with a HbA1c of &gt;7%&#xD;
&#xD;
          -  History of new cardiovascular event within the last 6 months (i.e., intervention,&#xD;
             percutaneous coronary intervention, vascular surgery, acute coronary syndrome [non&#xD;
             Q-wave myocardial infarction, Q-wave myocardial infarction, unstable angina) or&#xD;
             significant arrhythmia; or major intervention (e.g., cardiac surgery or angiography&#xD;
             plus stenting) scheduled&#xD;
&#xD;
          -  Concurrent or past medical history of congestive heart failure or pulmonary oedema&#xD;
&#xD;
          -  A presence of severe peripheral oedema or a medically serious fluid-related event&#xD;
&#xD;
          -  has significant cardiac, pulmonary, metabolic, renal, hepatic, gastrointestinal or&#xD;
             immunological conditions that, in the opinion of the Investigator and/or GSK medical&#xD;
             monitor, places the subject at an unacceptable risk as a participant in this trial&#xD;
&#xD;
          -  a history of malignancy in the last 5 years, except for surgically cured basal cell&#xD;
             carcinoma (&gt;2 years prior to first dosing)&#xD;
&#xD;
          -  a history of HIV, or chronic hepatitis B or positive C serology&#xD;
&#xD;
          -  a history of drug abuse&#xD;
&#xD;
          -  has participated in a clinical trial within the 3 months before the start of the study&#xD;
             for non-biological therapy; or within 6 months of a biological therapy&#xD;
&#xD;
          -  on a biological therapy or has received biological therapy within 6 months prior to&#xD;
             screening&#xD;
&#xD;
          -  has donated blood in excess of 500 mL within 56 days prior to dosing&#xD;
&#xD;
          -  The subject is at risk of non-compliance in following directions or adhering to study&#xD;
             restrictions&#xD;
&#xD;
          -  a history of drug or other allergy, which, in the opinion of the physician&#xD;
             responsible, contraindicates their participation&#xD;
&#xD;
          -  has anaemia defined by haemoglobin concentration &lt;11 g/dL for males or &lt;10 g/dL for&#xD;
             females&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-45130</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Glasgow</city>
        <state>Lanarkshire</state>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Glasgow</city>
        <state>Lanarkshire</state>
        <zip>G21 3UW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Glasgow</city>
        <state>Lanarkshire</state>
        <zip>G31 2ER</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Lithuania</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>This study has not been published in the scientific literature.</citation>
  </reference>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>September 21, 2006</study_first_submitted>
  <study_first_submitted_qc>September 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2006</study_first_posted>
  <last_update_submitted>October 24, 2016</last_update_submitted>
  <last_update_submitted_qc>October 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anti-inflammatory treatment</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosiglitazone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>ARA102198</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>ARA102198</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>ARA102198</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>ARA102198</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>ARA102198</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>ARA102198</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>ARA102198</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <pending_results>
    <submitted>July 6, 2017</submitted>
    <returned>February 1, 2018</returned>
    <submitted>March 5, 2018</submitted>
    <submission_canceled>August 15, 2018</submission_canceled>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

